" class="no-js "lang="en-US"> Personalis - Medtech Alert
Saturday, August 02, 2025
Personalis | MTA

Personalis

About Personalis

Personalis
Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. To enable cancer sequencing, Personalis' Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited.

Related Story

Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer

May 16 2023

Personalis, the National Cancer Center, and Ono Pharmaceutical today announced they have entered into a […]

Personalis Joins Top UK Cancer Research Organizations to Evaluate Earlier Cancer Recurrence Detection Through Groundbreaking Study

April 5 2023

Personalis, Cancer Research UK’s Cancer Research Horizons, University College London (UCL), and the Francis Crick […]

Personalis Selected for Clinical Research by AstraZeneca After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay

March 8 2023

Personalis, a leader in advanced genomics for precision oncology, today announced it will continue its […]

Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials

February 3 2023

Personalis, a leader in advanced genomics for precision oncology, and Moderna, a biotechnology company pioneering […]